Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer
The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Standard chemotherapy is associated with low response rates and short progression-free survival among patients with pretreated metastatic triple-negative breast cancer. Sacituzumab govitecan-hziy is an antibody-drug conjugate that combines a humanized monoclonal antibody, which targets the human trophoblast cell-surface antigen 2 (Trop-2), with SN-38, which is conjugated to the antibody by a cleavable linker. Sacituzumab govitecan-hziy enables delivery of high concentrations of SN-38 to tumors. METHODS: We conducted a phase 1/2 single-group, multicenter trial involving patients with advanced epithelial cancers who received sacituzumab govitecan-hziy intravenously on days 1 and 8 of each 21-day cycle until disease progression or unacceptable toxic effects. A total of 108 patients received sacituzumab govitecan-hziy at a dose of 10 mg per kilogram of body weight after receiving at least two previous anticancer therapies for metastatic triple-negative breast cancer. The end points included safety; the objective response rate (according to Response Evaluation Criteria in Solid Tumors, version 1.1), which was assessed locally; the duration of response; the clinical benefit rate (defined as a complete or partial response or stable disease for at least 6 months); progression-free survival; and overall survival. Post hoc analyses determined the response rate and duration, which were assessed by blinded independent central review. RESULTS: The 108 patients with triple-negative breast cancer had received a median of 3 previous therapies (range, 2 to 10). Four deaths occurred during treatment; 3 patients (2.8%) discontinued treatment because of adverse events. Grade 3 or 4 adverse events (in ≥10% of the patients) included anemia and neutropenia; 10 patients (9.3%) had febrile neutropenia. The response rate (3 complete and 33 partial responses) was 33.3% (95% confidence interval [CI], 24.6 to 43.1), and the median duration of response was 7.7 months (95% CI, 4.9 to 10.8); as assessed by independent central review, these values were 34.3% and 9.1 months, respectively. The clinical benefit rate was 45.4%. Median progression-free survival was 5.5 months (95% CI, 4.1 to 6.3), and overall survival was 13.0 months (95% CI, 11.2 to 13.7). CONCLUSIONS: Sacituzumab govitecan-hziy was associated with durable objective responses in patients with heavily pretreated metastatic triple-negative breast cancer. Myelotoxic effects were the main adverse reactions. (Funded by Immunomedics; IMMU-132-01 ClinicalTrials.gov number, NCT01631552.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The overall response rate was 33.3% (95% CI 24.6-43.1), with a median duration of response of 7.7 months (95% CI 4.9-10.8).”
From 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5) (2020) · cites this paper as [72]
In the citing paper
“Of the patients with a response to sacituzumab govitecan-hziy, 55.6% maintained their response for ≥6 months and 16.7% maintained their response for ≥12 months.”
From 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5) (2020) · cites this paper as [72]
Citations
Cites
Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer
Schmid, P., Adams, S., Rugo, H. S., Schneeweiss, A., Barrios, C. H., Iwata, H., Diéras, V., Hegg, R., Im, S.-A., Shaw Wright, G., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1809615 · Cited by 4,350
Self-citationTrastuzumab emtansine for HER2-positive advanced breast cancer
Verma, S., Miles, D., Gianni, L., Krop, I. E., Welslau, M., Baselga, J., Pegram, M., Oh, D.-Y., Diéras, V., Guardino, E., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1209124 · Cited by 3,834
Palbociclib and letrozole in advanced breast cancer
Finn, R. S., Martin, M., Rugo, H. S., Jones, S., Im, S.-A., Gelmon, K., Harbeck, N., Lipatov, O. N., Walshe, J. M., Moulder, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607303 · Cited by 3,007
Self-citationCombined BRAF and MEK inhibition in melanoma with BRAF V600 mutations
Flaherty, K. T., Infante, J. R., Daud, A., Gonzalez, R., Kefford, R. F., Sosman, J., Hamid, O., Schuchter, L., Cebon, J., Ibrahim, N., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1210093 · Cited by 2,810
Crizotinib in ROS1-Rearranged Non–Small-Cell Lung Cancer
Shaw, A. T., Ou, S.-H. I., Bang, Y.-J., Camidge, D. R., Solomon, B. J., Salgia, R., Riely, G. J., Varella-Garcia, M., Shapiro, G. I., Costa, D. B., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1406766 · Cited by 1,964
Breast cancer statistics, 2015: Convergence of incidence rates between black and white women
DeSantis, C. E., Fedewa, S. A., Goding Sauer, A., Kramer, J. L., Smith, R. A., & Jemal, A. (2016) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21320 · Cited by 1,252
Cortes, J., O'Shaughnessy, J., Loesch, D., Blum, J. L., Vahdat, L. T., Petrakova, K., Chollet, P., Manikas, A., Diéras, V., Delozier, T., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60070-6 · Cited by 1,094
Self-citationKohler, B. A., Sherman, R. L., Howlader, N., Jemal, A., Ryerson, A. B., Henry, K. A., Boscoe, F. P., Cronin, K. A., Lake, A., Noone, A.-M., et al. (2015) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djv048 · Cited by 915
Kawato, Y., Aonuma, M., Hirota, Y., Kuga, H., & Sato, K. (1991) · PubMed · Cited by 865
Goldenberg, D. M., Cardillo, T. M., Govindan, S. V., Rossi, E. A., & Sharkey, R. M. (2015) · Oncotarget · doi:10.18632/oncotarget.4318 · Cited by 495
Self-citation
Research works printed but not linked: 1
- 10.1002/(SICI)1097-0215(19980529)76:5<671::AID-IJC10>3.0.CO;2-7 · DOI · Paper page
Cited by
Items 701–800 of 874
Saravanan, R., Balasubramanian, V., Srikanth Swamy Swaroop, B., Naidu, J. K., Balasubramanian, N., Pitani, R. S., Vittalraj, P., Dev, B., Sundaram, S., Shanmugasundaram, G., et al. (2025) · Cancer Investigation · doi:10.1080/07357907.2025.2595303 · Cited by 1
“According to the results of a clinical investigation published by Bardia et al (18), an ADC established by Immunomedics, by conjugating Irinotecan metabolite, Sn-38 (a topo-isomerase inhibitor) to Sacituzumab Govitecan (IMMU-132 - a humanized anti-TROP2 antibody), had a significant and robust anti-tumorigenic response…”
Henderson, B. D., Mcmahon, L., Lewis, F., Marion, C., Hurley, S. M., Gately, K. A., Narinda, I., Kanjuga, M., Norris, L. A., Martin, C. M., et al. (2026) · The Journal of Liquid Biopsy · doi:10.1016/j.jlb.2026.100479 · Cited by 1
“In metastatic TNBC, sacituzumab govitecan (SG), a TROP-2-targeted ADC, almost doubled progression-free and overall survival compared to chemotherapy in the phase III ASCENT trial [7,8].”
Tirinescu, R., Pah, A.-M., Tirinescu, A., Mateescu, D.-M., & Mureșan, C.-O. (2026) · Medicina · doi:10.3390/medicina62091664 · Cited by 1
Trophoblast Cell Surface Antigen 2 Expression in Thymic Carcinoma: Brief Report
Kurokawa, K., Asao, T., Hayashi, T., Kishikawa, S., Kanamori, K., Shukuya, T., Miyashita, Y., Nakamura, I., Miyawaki, T., Kanemaru, R., et al. (2024) · JTO Clinical and Research Reports · doi:10.1016/j.jtocrr.2024.100693 · Cited by 3
Pharmacoepidemiology and pharmacovigilance post-marketing drug safety studies
(2024) · Frontiers research topics · doi:10.3389/978-2-8325-5380-0 · Cited by 1
Martorana, F., Sanò, M. V., Fabi, A., Paris, I., Leonardi, V. B., Bini, G., Maiorana, O., Vigneri, P. G., Gebbia, V., Scandurra, G., et al. (2025) · American Journal of Clinical Oncology · doi:10.1097/coc.0000000000001201 · Cited by 1
An update on the therapeutic options for metastatic thymomas and thymic carcinomas
Masui, Y., & Okuma, Y. (2025) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2025.2519858 · Cited by 2
“In contrast, normal thymic tissues have limited Trop-2 expression [67], indicating that this protein is a promising therapeutic target.”
Santin, A. D., Roque, D. M., Siegel, E. R., Ettorre, V. M., Greenman, M. P., McNamara, B. C., Papatla, K., Kailasam, A., Azodi, M., Buza, N., et al. (2025) · Clinical Cancer Research · doi:10.1016/j.ijgc.2025.102143 · Cited by 1
Self-citationAffinity-optimized TROP2 antibodies support potent antitumor activity in antibody–drug conjugates
Yamaguchi, A., Hong, J., Li, L., Kobayashi, K., Yamazaki, C. M., Ha, S. Y. Y., Anami, Y., Xiong, W., Liu, J., An, Z., et al. (2026) · Antibody Therapeutics · doi:10.1093/abt/tbag011 · Cited by 1
Önder, F. C., Kahraman, N., Siyah, P., Durdağı, S., Atıcı, E. B., Atalay, P., Dilmaç, S., Özyurt, R., Kara, G., Gul, O. A., et al. (2026) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2026.151860 · Cited by 2
Mairé, M., Bouteiller, F., Chakiba, C., Jacot, W., Geiss, R., Ung, M., Gonçalvès, A., Frenel, J., Bailleux, C., Perrin, C., et al. (2026) · The Breast · doi:10.1016/j.breast.2026.104816 · Cited by 1
“For mTNBC, new treatment option such as immunotherapy (pembrolizumab), PARP inhibitors or antibody-drug conjugates (sacituzumab-govitecan) have recently been disclosed [28 – 30].”
Xu, Y., Li, F., Cui, Z., Xie, H., Xu, L., Lin, Y., Li, T., Li, N., Cao, D., He, W., et al. (2026) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-26-0395 · Cited by 1
Antibody–drug conjugates: a practical review on clinical management of toxicities
Palma, A. D., Marenco, M., Mancini, S., Palaia, I., Barchiesi, G., Donato, V. D., Perniola, G., Petrella, M. C., Muzii, L., & Tomao, F. (2026) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2026.2685304 · Cited by 1
“R analyses from IMMU-132–01 [96] and ASCENT [50] showed that higher average exposure was associated with increased objective response rates but also with a higher risk of grade ≥3 neutropenia, highlighting an exposure-dependent trade-off between efficacy and safety [97].”
Antibody-drug conjugates in breast cancer: from mechanism to revolutionizing clinical practice
Li, S. B., Xu, Z., Ruan, W., Wang, X. J., Yu, H., Yi, M., & Fu, P. (2026) · Molecular Cancer · doi:10.1186/s12943-026-02711-9 · Cited by 1
“The subsequent emergence of next-generation ADCs, such as trastuzumab deruxtecan (T-DXd) [10, 11] and sacituzumab govitecan (SG) [12, 13], has further revolutionized the treatment.”
CDK4/6 Inhibitors in Breast Cancer Therapy: Mechanisms, Resistance, and Emerging Opportunities
Chinea, L. E., Hauer, C., Pal, K., Chang, H. L., & Chan, I. S. (2026) · Targeted Oncology · doi:10.1007/s11523-026-01232-1 · Cited by 2
“Sacituzumab govitecan (SG), a TROP2-directed ADC with a topoisomerase inhibitor payload, was initially tested and approved in triple-negative breast cancer [128].”
Addissie, Y. A., Greer, Y. E., Nair, J. R., & Lipkowitz, S. (2026) · Breast Cancer Research · doi:10.1186/s13058-026-02318-4 · Cited by 1
“One molecular target being studied for TNBC therapy is human trophoblast cell surface antigen 2 (Trop2), which is a monomeric transmembrane calcium signal transducer that is highly expressed in a variety of tumors including prostate, pancreatic and breast cancers [7–9].”
Schneeweiß, A., Denkert, C., Fasching, P. A., Fremd, C., Gluz, O., Kolberg‐Liedtke, C., Loibl, S., & Lück, H. (2019) · Senologie - Zeitschrift für Mammadiagnostik und -therapie · doi:10.1055/a-0977-4248 · Cited by 1
De, S. K. (2023) · Medicines for Cancer · doi:10.1016/b978-0-443-13312-1.00009-x · Cited by 1
DNA intercalation and topoisomerase inhibition
Avendaño, C., & Menéndez, J. C. (2023) · Elsevier eBooks · doi:10.1016/b978-0-12-818549-0.00010-8 · Cited by 1
Antibody–drug conjugate: Emerging trend for targeted treatment
Pandey, M., Gorain, B., Kushwaha, S. P., Gulati, N., Mayuren, J., & Butt, A. M. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-91663-9.00013-8 · Cited by 1
Rygiel, K. (2023) · BENTHAM SCIENCE PUBLISHERS eBooks · doi:10.2174/9789815196023123010004 · Cited by 1
Anti-Cancer Activity and Mechanism of Resveratrol Against Triple-Negative Breast Cancer
Zhang, X., Wu, F., Shi, S., Chen, P., Jin, M., & Zheng, N. (2024) · Journal of Biobased Materials and Bioenergy · doi:10.1166/jbmb.2024.2435 · Cited by 1
Maßnahmen bei Diarrhö unter Chemotherapie und zielgerichteter Therapie
Sommer, K., Wulf, S., & Gallwas, J. K. S. (2024) · DMW - Deutsche Medizinische Wochenschrift · doi:10.1055/a-2204-5395 · Cited by 1
Kulemzin, S. V., Gorchakov, A. A., & Taranin, A. V. (2019) · Cellular Therapy and Transplantation · doi:10.18620/ctt-1866-8836-2019-8-4-19-28 · Cited by 1
Banys‐Paluchowski, M., & Krawczyk, N. (2021) · Der Onkologe · doi:10.1007/s00761-021-00899-7 · Cited by 1
Monoclonal Antibody-Directed Therapy
Kayser, V., & Datta‐Mannan, A. (2022) · MDPI eBooks · doi:10.3390/books978-3-0365-2872-4 · Cited by 1
Current status of nanomedicine for breast cancer treatment
Fraguas‐Sánchez, A. I., Martín‐Sabroso, C., Fernández-Carballido, A. M., & Torres‐Suárez, A. I. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-824476-0.00014-0 · Cited by 1
Precision Medicine, Imprecise Health Care Justice
Fleck, L. M. (2022) · Oxford University Press eBooks · doi:10.1093/oso/9780197647721.003.0004 · Cited by 1
Belac-Lovasić, I., Bašić-Koretić, M., Podolski, P., Plavetić, N. D., Silovski, T., Pleština, S., Jazvić, M., Soldić, Ž., Šeparović, R., Vuger, A. T., et al. (2022) · Liječnički vjesnik · doi:10.26800/lv-144-9-10-2 · Cited by 2
Management of Metastatic Triple-negative Breast Cancer: Focus on Targeted Therapies
Keenan, J. C., Ryan, P. K., Medford, A. J., Spring, L. M., & Bardia, A. (2022) · touchREVIEWS in Oncology & Haematology · doi:10.17925/ohr.2022.18.2.98 · Cited by 1
Self-citationUpdated Austrian treatment algorithm for metastatic triple-negative breast cancer
Bartsch, R., Rinnerthaler, G., Petru, E., Egle, D., Gnant, M., Balić, M., Sliwa, T., & Singer, C. F. (2023) · Wiener klinische Wochenschrift · doi:10.1007/s00508-023-02254-9 · Cited by 2
Fishman, M. (2019) · Translational Andrology and Urology · doi:10.21037/tau.2019.09.19 · Cited by 1
How can we create precision immunotherapy as standard in breast cancer?
Hartman, Z. C. (2021) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2021.1951241 · Cited by 1
Omori, S., Muramatsu, K., Kawata, T., Miyawaki, E., Miyawaki, T., Mamesaya, N., Kawamura, T., Kobayashi, H., Nakashima, K., Wakuda, K., et al. (2021) · Research Square · doi:10.21203/rs.3.rs-270630/v1 · Cited by 1
Ávila, J., & Leone, J. P. (2023) · Annals of Translational Medicine · doi:10.21037/atm-22-5266 · Cited by 1
Bessede, A., Peyraud, F., Besse, B., Cousin, S., Cabart, M., Chomy, F., Rey, C., Lara, O., Odin, O., Nafia, I., et al. (2024) · doi:10.1158/1078-0432.c.7077754 · Cited by 1
Gong, X., Gu, L., Yang, D., He, Y., Li, Q., Qin, H., & Wang, Y. (2025) · eLife · doi:10.7554/elife.100923.2 · Cited by 1
Turner, S., Bhattacharjee, A., Diao, L., Zhao, M., Zhang, S., & Yoon, S. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.07.21.665993 · Cited by 1
Die systemische Behandlung des triple-negativen Mammakarzinoms
Landin, J., & Vetter, M. H. F. (2019) · InFo Hämatologie + Onkologie · doi:10.1007/s15004-019-6471-7
Antikörperkonjugat erfolgreich bei triple-negativem Mammakarzinom
Starostzik, C. (2019) · gynäkologie + geburtshilfe · doi:10.1007/s15013-019-1764-3
Metastasiertes triple-negatives Mammakarzinom
Krome, S. (2019) · Onkologische Welt · doi:10.1055/a-0874-1537
Positive Entwicklung beim triple-negativen Mammakarzinom
Eichbaum, M. H. R. (2021) · TumorDiagnostik & Therapie · doi:10.1055/a-1256-2688
Update Mammakarzinom 2020 Teil 3 – frühes Mammakarzinom
Huober, J., Schneeweiß, A., Hartkopf, A. D., Müller, V., Lux, M. P., Janni, W., Ettl, J., Belleville, E., Thill, M., Fasching, P. A., et al. (2021) · Senologie - Zeitschrift für Mammadiagnostik und -therapie · doi:10.1055/a-1331-8551
“Der ADC Sacituzumab Govitecan, welcher beim TNBC in der metastasierten Situation eine deutliche Wirksamkeit gezeigt hatte [70], wird momentan in ein größeres Studienkonzept für HER2-negative Patientinnen in der postneoadjuvanten Situation integriert (SASCIA-Studie [71]).”
BackgroundA narrative review of immune checkpoint inhibitors in early stage triple negative breast cancer
Beltran-Bless, A.-A., & Ng, T. L. (2021) · Precision Cancer Medicine · doi:10.21037/pcm-20-64
“, Sacituzumab govitecan) are also likely to be tested in combination with ICIs in early TNBC (5,40-42).”
BackgroundImmunonkologie – Für Brustkrebs doch geeignet? Neue Ansätze beim triple-negativen Mammakarzinom
Lüftner, D., & Busse, A. (2021) · Der Gynäkologe · doi:10.1007/s00129-021-04791-8
2019–2020 Drug Updates in Solid Tumors
Hanna, K. S. (2021) · Journal of the Advanced Practitioner in Oncology · doi:10.6004/jadpro.2021.12.3.11
Characteristics and therapy of advanced cancer diseases
Taghizadeh, H. (2021)
Signifikanter Überlebensvorteil durch Sacituzumab-Govitecan beim TNBC
Weiße, S., Quaester, S., & Dunst, J. (2021) · InFo Hämatologie + Onkologie · doi:10.1007/s15004-021-8782-8
Lux, M. P., Schneeweiß, A., Hartkopf, A. D., Müller, V., Janni, W., Belleville, E., Stickeler, E., Thill, M., Fasching, P. A., Kolberg, H. C., et al. (2021) · Senologie - Zeitschrift für Mammadiagnostik und -therapie · doi:10.1055/a-1491-3672
“In den USA wurde Sacituzumab-Govitecan bereits auf Basis der guten Daten der frühen Therapiestudie zugelassen [40].”
BackgroundSacituzumab govitecan in breast cancer
Wang, X., Chen, J., Xiao, H., & Shi, Y. (2021) · Translational Breast Cancer Research · doi:10.21037/tbcr-21-28
'Ik ben van nette komaf', of : Hoe een boer kapelaan werd
van Hees, H. (1982) · Utrecht University Repository (Utrecht University)
Ongoing Clinical Studies and Future Directions
Nasrazadani, A., Marti, J. L. G., Hyder, T., Gorantla, V. C., & Brufsky, A. (2021) · Springer eBooks · doi:10.1007/978-3-030-88020-0_15
Therapiealgorithmen für das Mammakarzinom
Blohmer, J., Schneeweiß, A., Bauerfeind, I., Fehm, T. N., Müller, V., Thomssen, C., Witzel, I., Wöckel, A., & Janni, W. (2021) · Der Onkologe · doi:10.1007/s00761-021-01060-0
Treatment of Metastatic Bladder Cancer
Fujiwara, Y., Miyashita, H., & Galsky, M. D. (2022) · Springer eBooks · doi:10.1007/978-3-030-89891-5_19
Update Mammakarzinom 2021 Teil 2 – fortgeschrittene Stadien, Langzeitfolgen und Biomarker
Ditsch, N. C., Stickeler, E., Behrens, A. S., Belleville, E., Fasching, P. A., Fehm, T. N., Hartkopf, A. D., Jackisch, C., Janni, W., Kolberg‐Liedtke, C., et al. (2022) · Senologie - Zeitschrift für Mammadiagnostik und -therapie · doi:10.1055/a-1755-5626
Breast Cancer—Essential news of current guidelines
Strasser‐Weippl, K. (2022) · memo - Magazine of European Medical Oncology · doi:10.1007/s12254-022-00799-5
Aspectos clínicos y terapéuticos del carcinoma de mama metastásico triple negativo
Olvera, J. A. S., Pérez, D. O., Noguez-Ramos, A., Medina, R. G. R., Cantero, A. J., & de la Borbolla, L. F. M.-C. (2022) · Anales Médicos de la Asociación Médica del Centro Médico ABC · doi:10.35366/106027
Therapie des triple-negativen Mammakarzinoms
Maier, A. M., Hester, A., Harbeck, N., & Würstlein, R. (2022) · InFo Hämatologie + Onkologie · doi:10.1007/s15004-022-9153-9
Kok, V. C. (2022) · Exploratory Research and Hypothesis in Medicine · doi:10.14218/erhm.2022.00087 · Cited by 1
Precision Medicine, Diffuse Wickedness
Fleck, L. M. (2022) · Oxford University Press eBooks · doi:10.1093/oso/9780197647721.003.0003
Selected Examples of Ongoing Large Genotype–Drug Matching Precision Cancer Medicine Trials
Fleck, L. M. (2022) · Oxford University Press eBooks · doi:10.1093/oso/9780197647721.005.0001
Precision Medicine, Precision Health: Finding Just and Reasonable Trade-offs
Fleck, L. M. (2022) · Oxford University Press eBooks · doi:10.1093/oso/9780197647721.003.0008
Public Reason, Precision Medicine: Future Hopes
Fleck, L. M. (2022) · Oxford University Press eBooks · doi:10.1093/oso/9780197647721.003.0009
Fleck, L. M. (2022) · Oxford University Press eBooks · doi:10.1093/oso/9780197647721.002.0007
Fleck, L. M. (2022) · Oxford University Press eBooks · doi:10.1093/oso/9780197647721.005.0002
20 Most Expensive Drugs in the United States, 2021
Fleck, L. M. (2022) · Oxford University Press eBooks · doi:10.1093/oso/9780197647721.005.0003
Fleck, L. M. (2022) · Oxford University Press eBooks · doi:10.1093/oso/9780197647721.002.0003
Precision Medicine: An Introduction to Its Ethical Ambiguity
Fleck, L. M. (2022) · Oxford University Press eBooks · doi:10.1093/oso/9780197647721.003.0001
Rational Democratic Deliberation: Disciplining Wicked Challenges Justly
Fleck, L. M. (2022) · Oxford University Press eBooks · doi:10.1093/oso/9780197647721.003.0006
Rational Democratic Deliberation: Seeking Justice Together
Fleck, L. M. (2022) · Oxford University Press eBooks · doi:10.1093/oso/9780197647721.003.0005
Fleck, L. M. (2022) · Oxford University Press eBooks · doi:10.1093/oso/9780197647721.002.0004
Precision Medicine: Hope, Hype, and Hysteria
Fleck, L. M. (2022) · Oxford University Press eBooks · doi:10.1093/oso/9780197647721.003.0002
Obligatory Social Beneficence: The Sufficientarian Challenge
Fleck, L. M. (2022) · Oxford University Press eBooks · doi:10.1093/oso/9780197647721.003.0007
Nanobiotherapeutic strategies to target immune microenvironment of triple-negative breast cancer.
Chang, Q., Chang, L., Li, M., Fan, L., Bao, S., Wang, X., & Liu, L. (2022) · PubMed · Cited by 2
Monoclonal Antibody and Targeted Toxin Therapy
Bast, R. C., & Zalutsky, M. R. (2022) · Wiley eBooks · doi:10.1002/9781119000822.hfcm065.pub2
DNA Topoisomerase Targeting Drugs
Thomas, A., Bates, S. E., Figg, W. D., & Pommier, Y. G. (2022) · Wiley eBooks · doi:10.1002/9781119000822.hfcm060.pub2
Tripathy, D., Makhnoon, S., Arun, B. K., Şahin, A. A., Kettner, N. M., Damodaran, S., Keyomarsi, K., Yang, W. T., Hunt, K. K., Clemens, M. W., et al. (2022) · Wiley eBooks · doi:10.1002/9781119000822.hfcm109.pub2
Ovarian carcinosarcoma (a literature review)
Beishembaev, A. М., Иосифович, Ж. К., Choi, E. D., Turkmenov, A. A., & Moldobekova, A. K. (2022) · Obstetrics Gynecology and Reproduction · doi:10.17749/2313-7347/ob.gyn.rep.2022.295
“Нет консенсуса по поводу исследуемых терапев-тических препаратов второй линии, таких как, напри-мер, пазопаниб [18, 19], пембролизумаб [14], сациту-зумаб говитекан [20], олапариб [21].”
SOP Maßnahmen bei Diarrhö unter Chemotherapie und zielgerichteter Therapie
Sommer, K., Wulf, S., & Gallwas, J. K. S. (2023) · Frauenheilkunde up2date · doi:10.1055/a-1705-8903
The Role of Monoclonal Antibodies in Breast Cancer
Luo, J., Chang, X., Wang, S. Y., & Yu, H. (2023) · Highlights in Science Engineering and Technology · doi:10.54097/hset.v36i.5742
Decary, S., Berne, P., Nicolazzi, C., Lefebvre, A., Dabdoubi, T., Cameron, B., Rival, P., Devaud, C., Prades, C., Bouchard, H., et al. (2023) · doi:10.1158/1078-0432.c.6529818
DeLucia, D. C., Cardillo, T. M., Ang, L. S., Labrecque, M. P., Zhang, A., Hopkins, J. E., Sarkar, N. D., Coleman, I. M., da Costa, R. M. G., Corey, E., et al. (2023) · doi:10.1158/1078-0432.c.6530156.v1
Tsujii, S., Serada, S., Fujimoto, M., Uemura, S., Namikawa, T., Nomura, T., Murakami, I., Hanazaki, K., & Naka, T. (2023) · doi:10.1158/1535-7163.c.6543376
Tsujii, S., Serada, S., Fujimoto, M., Uemura, S., Namikawa, T., Nomura, T., Murakami, I., Hanazaki, K., & Naka, T. (2023) · doi:10.1158/1535-7163.22522438
Data from Efficacy of Rac and Cdc42 Inhibitor MBQ-167 in Triple-negative Breast Cancer
Cruz‐Collazo, A., Ruiz-Calderón, J. F., Picon, H. M., Borrero-García, L. D., Lopez, I., Castillo‐Pichardo, L., Maldonado, M. D. M., Duconge-Soler, J., Medina, J. I., Bayro, M. J., et al. (2023) · doi:10.1158/1535-7163.c.6543291
Data from Development of Novel Antibody–Camptothecin Conjugates
Lyski, R. D., Bou, L., Lau, U. Y., Meyer, D. W., Cochran, J. H., Okeley, N. M., Emmerton, K. K., Zapata, F., Simmons, J. K., Trueblood, E. S., et al. (2023) · doi:10.1158/1535-7163.c.6543066.v1
Data from Development of Novel Antibody–Camptothecin Conjugates
Lyski, R. D., Bou, L., Lau, U. Y., Meyer, D. W., Cochran, J. H., Okeley, N. M., Emmerton, K. K., Zapata, F., Simmons, J. K., Trueblood, E. S., et al. (2023) · doi:10.1158/1535-7163.c.6543066
Shah, P. D., Huang, A. C. C., Xu, X., Orlowski, R. J., Amaravadi, R. K., Schuchter, L. M., Zhang, P. J., Tchou, J. C., Matlawski, T., Cervini, A., et al. (2023) · doi:10.1158/2767-9764.c.6547846.v1
Coates, J. T. T., Sun, S., Leshchiner, I., Thimmiah, N., Martin, E. E., McLoughlin, D. E., Danysh, B. P., Slowik, K., Jacobs, R. A., Rhrissorrakrai, K., et al. (2023) · doi:10.1158/2159-8290.c.6549032
Self-citationRaheem, F., & Shah, V. S. (2023) · IntechOpen eBooks · doi:10.5772/intechopen.110804
Cancers du sein triples négatifs, l’innovation thérapeutique enfin accessible
Béguinot, M., Fondrevelle, M.-E., Paradisi‐Prieur, L., & Archinard, C. (2022) · Sages-Femmes · doi:10.1016/j.sagf.2022.01.008
Shah, P. D., Huang, A. C. C., Xu, X., Orlowski, R. J., Amaravadi, R. K., Schuchter, L. M., Zhang, P. J., Tchou, J. C., Matlawski, T., Cervini, A., et al. (2023) · doi:10.1158/2767-9764.c.6547846
Burk, S. R., & Morrione, A. (2023) · Annals of Research in Oncology · doi:10.48286/aro.2023.65
New Advances in Prognostic Biomarker of Triple-Negative Breast Cancer
曹, 钰. (2023) · Advances in Clinical Medicine · doi:10.12677/acm.2023.13112381
Agostinetto, E., Gombos, A., & Piccart, M. J. (2023) · Springer eBooks · doi:10.1007/978-3-030-93702-7_2-1
Chehal, A. A., ALakkad, A., & Dreier, N. (2024) · GSC Advanced Research and Reviews · doi:10.30574/gscarr.2024.18.3.0083
“When hRS7, either in its free form or conjugated to SN-38, binds to Trop-2, it is internalized by the tumor cell and delivers SN-38 to the site (15).”
BackgroundClinical toxicity of antibody–drug conjugates
Gupta, T., Panchal, M., Pawar, V., Tekade, M., Gandhi, S., & Tekade, R. K. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-15842-1.00012-0 · Cited by 1
Wang, Z., Lu, R., Jiang, M., Chu, X., & Zhou, R. (2024) · SSRN Electronic Journal · doi:10.2139/ssrn.4790904
Joshi, P. S., Ayyagari, V. N., Kandel, S., Modur, V., Iqbal, M., Robinson, K., Gao, J., & Rao, K. (2024) · BioMed Research International · doi:10.1155/2024/8544837
“Historically, triple-negative breast cancers have lacked a therapeutic target, and targeting the ras oncogene has been challenging, but the recent FDA approval of sacituzu-mab govitecan-hziy has shown that therapeutic targeting is possible as over 90% of these tumors express the Trop-2 protein [53].”
BackgroundCancer Nanomedicines in the Clinic: Coming of Age
Zaheer, S. (2024) · Springer eBooks · doi:10.1007/978-981-97-3545-7_15
Metadata
- Authors
- Bardia, A., Mayer, I. A., Vahdat, L. T., Tolaney, S. M., Isakoff, S. J., Diamond, J. R., O’Shaughnessy, J., Moroose, R. L., Santin, A. D., Abramson, V. G., Shah, N. C., Rugo, H. S., Goldenberg, D. M., Sweidan, A. M., Iannone, R., Washkowitz, S., Sharkey, R. M., Wegener, W. A., & Kalinsky, K.
- Affiliations
- Harvard University (US)
- Vanderbilt University (US)
- Cornell University (US)
- Orlando Health (US)
- University of California, San Francisco (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2019-02-21
- Volume
- 380
- Issue
- 8
- Pages
- 741-751
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2917403028
- Cited by
- 874
- References
- 37
- Citations by year
- 2026: 76 · 2025: 103 · 2024: 111 · 2023: 125 · 2022: 167 · 2021: 167 · 2020: 91 · 2019: 32
- FWCI
- 36.24
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Immunomedics Inc
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
- Health Sciences › Medicine › Oncology › Advanced Breast Cancer Therapies
- Health Sciences › Medicine › Oncology › Cancer Treatment and Pharmacology
- Keywords
- sacituzumab govitecan, antibody-drug conjugates, metastatic triple-negative breast cancer, TROP2, SN-38, refractory disease, objective response rate, duration of response, progression-free survival, overall survival, safety, febrile neutropenia, anemia, neutropenia
- MeSH terms
- Irinotecan, Progression-Free Survival, Adult, Aged, Aged, 80 and over, Anemia, Antigens, Neoplasm, Antineoplastic Agents, Camptothecin, Diarrhea, Dose-Response Relationship, Drug, Female, Humans, Infusions, Intravenous, Male, Middle Aged, Neutropenia, Cell Adhesion Molecules, Survival Rate, Immunoconjugates, Antibodies, Monoclonal, Humanized, Triple Negative Breast Neoplasms
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.